This content is for informational purposes only and is not a substitute for professional advice.
Alpha-GPC is a choline donor, so the test should ask whether it improves a specific work output without headache, low mood, GI effects, or sleep disruption. Treat it as a single-compound trial with dose windows, not as a hidden part of a focus blend.
Test criteria
Alpha-GPC earns a trial only when the label is clear, the user has a defined focus goal, and medications or cardiovascular risk do not make clinician review necessary.
| Design choice | Recommended setting |
|---|---|
| Outcome | Deep-work minutes, task completion, or reaction task |
| Timing | Same morning window |
| Confounders | Fixed caffeine, sleep target, meal pattern |
| Trial length | 4-8 comparable work sessions |
| Stop markers | Headache, irritability, low mood, insomnia, GI symptoms |
Protocol
Run a baseline week first. Record focus score, work output, sleep duration, caffeine dose, and mood. Then test Alpha-GPC at the lowest reasonable labeled dose on comparable days only. Do not add racetams, nicotine, extra caffeine, or other cholinergic products during the trial.
If the benefit appears only on exhausted days, Alpha-GPC may be masking sleep debt rather than improving baseline performance. If headache or low mood appears, stop and do not solve it by adding more stack complexity.
Decision table
| Result | Decision |
|---|---|
| Better output, no adverse effects | Continue short-term and retest later |
| Better feel, no output change | Do not upgrade the score |
| Headache or low mood | Stop |
| Sleep worsens | Stop or move timing earlier after review |
Disclosure
Unfair does not sell Alpha-GPC. In Unfair, log product form, dose, timing, and adverse effects so the ranked output does not overvalue subjective stimulation.
References
NIH Dietary Supplement Label Database. Alpha-GPC label search. https://dsld.od.nih.gov/
↩NIH Office of Dietary Supplements. Choline fact sheet. https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/
↩Lee G, et al. Alpha-GPC and stroke risk observational study. https://pubmed.ncbi.nlm.nih.gov/34817582/
↩